Surgical Science Q2 2024: Solid sequential recovery, decent outlook - Redeye

Redeye updates its estimates following Surgical Science’s Q2 2024 report, which featured a sequential recovery after the company’s weak Q1. Potential large orders in Educational Products might fuel sales growth in H2 2024e and 2025e. Further, Intuitive’s broader da Vinci 5 rollout should boost Industry/OEM growth in 2025e. We finetune our estimates and valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/1033802/surgical-science-q2-2024-solid-sequential-recovery-decent-outlook?utm_source=finwire&utm_medium=RSS